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Dramatically improved survival in multiple myeloma
patients in the recent decade:  results from a
Swedish population-based study 
Multiple myeloma (MM) is generally considered an
incurable disease. In recent decades, new treatment alter-
natives have changed both the clinical course of the dis-
ease and improved survival.1 Results from previous pop-
ulation-based studies in Sweden for patients diagnosed
until 2003 have shown an increased survival rate in
patients up to 70 years old at diagnosis,2 and studies from
the USA have shown improved long-term survival in
patients between 65 to 80 years old at diagnosis, and
reduced early mortality in all age groups in recent years.3
Subsequently, clinical trials have shown that using novel
agents as first-line treatment can further improve survival
in MM.4 However, there remains the unanswered ques-
tion of  how the use of immunomodulatory drugs and
proteasome inhibitors as first-line treatment of MM
affects survival in a large population-based patient
cohort. Real-world data, such as population-based stud-
ies, are very important tools to evaluate this, since the
included participants in clinical trials, for the most part,
are generally not representative of the whole MM patient
group, which compromises their generalizability.5
We performed a large population-based study using the
Swedish Cancer Register and included 21,502 MM
patients diagnosed over a 40-year period in order to
define changes in survival in all patients with MM from
1973 to 2013. 
Patients diagnosed with MM in the period from
January 1st 1973 to December 31st 2013 were identified
from the Swedish Cancer Register, a centralized, nation-
wide register that contains information, going back to
1958, on patients diagnosed with malignant disorders in
Sweden. Information on sex, date of birth, date of diag-
nosis, and date of death were collected. Information on
clinical stage and laboratory results were not available for
these patients. 
Relative survival ratios (RSRs) were used to provide a
measure for the excess mortality of MM patients in rela-
tion to a comparable group from the general population,
irrespective of whether the excess mortality is directly or
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Table 1. Relative survival ratios for patients diagnosed with multiple myeloma in Sweden, stratified by age group and calendar period at diag-
nosis.
Calendar Period
Age at diagnosis RSR (95% CI) RSR (95% CI) RSR (95% CI) RSR (95% CI)
1973-1982     1983-1992     1993-2002     2003-2013     
Three-month RSRs
20-40 0.94 (0.82 to 0.98) 0.98 (0.87 to 1.00) 0.96 (0.83 to 0.99) 0.98 (0.88 to 1.00)
41-50 0.95 (0.90 to 0.97) 0.96 (0.93 to 0.98) 0.98 (0.96 to 0.99) 0.98 (0.95 to 0.99)
51-60 0.90 (0.88 to 0.92) 0.94 (0.91 to 0.95) 0.96 (0.94 to 0.97) 0.98 (0.97 to 0.99)
61-70 0.87 (0.85 to 0.89) 0.92 (0.91 to 0.94) 0.93 (0.92 to 0.94) 0.96 (0.95 to 0.97)
71-80 0.81 (0.79 to 0.83) 0.87 (0.86 to 0.89) 0.88 (0.86 to 0.89) 0.92 (0.91 to 0.94)
>80 0.68 (0.64 to 0.72) 0.76 (0.73 to 0.79) 0.81 (0.78 to 0.83) 0.84 (0.82 to 0.86)
One-year RSRs
20-40 0.92 (0.79 to 0.97) 0.92 (0.81 to 0.97) 0.91 (0.78 to 0.97) 0.92 (0.81 to 0.97)
41-50 0.82 (0.75 to 0.87) 0.86 (0.81 to 0.90) 0.94 (0.90 to 0.96) 0.93 (0.89 to 0.96)
51-60 0.75 (0.72 to 0.78) 0.84 (0.81 to 0.87) 0.91 (0.88 to 0.93) 0.92 (0.90 to 0.94)
61-70 0.74 (0.72 to 0.76) 0.80 (0.77 to 0.82) 0.84 (0.82 to 0.86) 0.88 (0.86 to 0.90)
71-80 0.66 (0.63 to 0.68) 0.73 (0.71 to 0.75) 0.73 (0.70 to 0.75) 0.80 (0.79 to 0.82)
>80 0.49 (0.45 to 0.54) 0.55 (0.51 to 0.59) 0.62 (0.58 to 0.65) 0.66 (0.63 to 0.69)
Five-year RSRs
20-40 0.48 (0.34 to 0.62) 0.57 (0.43 to 0.70) 0.67 (0.51 to 0.78) 0.59 (0.43 to 0.72)
41-50 0.47 (0.39 to 0.55) 0.50 (0.43 to 0.56) 0.61 (0.55 to 0.67) 0.70 (0.62 to 0.76)
51-60 0.36 (0.33 to 0.40) 0.44 (0.40 to 0.48) 0.56 (0.52 to 0.59) 0.62 (0.58 to 0.66)
61-70 0.31 (0.29 to 0.34) 0.34 (0.32 to 0.37) 0.36 (0.33 to 0.39) 0.48 (0.45 to 0.51)
71-80 0.24 (0.21 to 0.26) 0.28 (0.26 to 0.31) 0.24 (0.22 to 0.26) 0.34 (0.31 to 0.37)
>80 0.14 (0.10 to 0.18) 0.14 (0.11 to 0.17) 0.16 (0.13 to 0.19) 0.15 (0.12 to 0.19)
Ten-year RSRs
20-40 0.38 (0.25 to 0.52) 0.30 (0.18 to 0.43) 0.48 (0.33 to 0.62) 0.45 (0.28 to 0.61)
41-50 0.21 (0.15 to 0.28) 0.31 (0.25 to 0.38) 0.39 (0.32 to 0.45) 0.41 (0.29 to 0.54)
51-60 0.16 (0.13 to 0.19) 0.18 (0.15 to 0.22) 0.28 (0.24 to 0.31) 0.36 (0.30 to 0.43)
61-70 0.11 (0.09 to 0.13) 0.14 (0.12 to 0.16) 0.14 (0.12 to 0.16) 0.22 (0.18 to 0.27)
71-80 0.06 (0.05 to 0.08) 0.08 (0.07 to 0.10) 0.08 (0.06 to 0.10) 0.13 (0.09 to 0.17)
>80 0.05 (0.02 to 0.12) 0.05 (0.03 to 0.10) 0.02 (0.01 to 0.05) 0.08 (0.04 to 0.17)
RSR: relative survival ratio; CI: confidence interval.
indirectly associated with the disease.6 RSR is defined as
the observed survival in the patient group divided by the
expected survival of the general population. The Ederer II
method was used to estimate the expected survival in the
Swedish population life-tables, stratified by age, sex, and
calendar time. RSRs with 95% confidence intervals (CIs)
were estimated for one, five and ten years for four calen-
dar periods; 1973-1982, 1983-1992, 1993-2002 and
2003-2013, and furthermore for six age categories (20-40,
41-50, 51-60, 61-70, 71-80 and >80). Short-term survival,
as defined by RSR for the first three months after MM
diagnosis was also defined for all calendar periods.
Additionally, we modeled relative survival using flexi-
ble parametric relative survival models7 with time since
diagnosis modeled using natural splines with five degrees
of freedom. Age at diagnosis and calendar period were
modeled as categorical variables in some models to pro-
duce tables of hazard ratios, but also modelled as natural
splines, each with four degrees of freedom, to illustrate
temporal trends in relative survival as smooth flexible
functions.     
In the period from January 1st 1973 to December 31st
2013, a total of 21,502 patients with MM were reported
to the Swedish Cancer Register. Males constituted 11,655
(54%) and females 9847 (46%). Overall, three-month,
one-year, five-year, and ten-year RSR improved in MM
patients diagnosed from 1973 to 2013 (Figure 1). The
five-year RSR also improved in all four calendar periods,
although the improvement was not significant between
the two first periods (the RSRs were 0.28 (95% CI: 0.27-
0.30), 0.31 (95% CI: 0.30-0.33), 0.33 (95% CI: 0.31-0.34),
and 0.41 (95% CI: 0.40-0.43), respectively). Similarly,
analysis of the Surveillance, Epidemiology, and End
Results 1975-2010 USA database, showed an improve-
ment of five-year survival in patients diagnosed between
1999-2005.8 A European multi-center study likewise
found that relative survival increased from 30% to 40%
between 1997 and 1999 and 2006 and 2008.9 The most
likely explanation for increased survival in the third cal-
endar period in our study is widespread treatment with
high-dose melphalan/autologous transplantation
(HDM/ASCT), introduced in the 1980’s, which was used
in many of the younger patients from 1994 on, at the
least.2 In Sweden, around 80% of patients under 65 years
at diagnosis received HDM/ASCT in 2008-2012.10 In the
last calendar period, the effect of thalidomide, lenalido-
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Figure 1. Relative survival ratios (RSRs) for patients diag-
nosed with multiple myeloma in Sweden, stratified by cal-
endar period. RSR: relative survival ratio; CI: confidence
interval.
mide and bortezomib is the most likely explanation of
increased survival, since thalidomide was introduced in
MM treatment in 1999 and bortezomib and lenalidomide
in the early 2000s.2,10 In the subsequent years, these new
agents were used more frequently as first-line treatment
of MM.11 From 2008 to 2012 the proportion of patients
receiving thalidomide, bortezomib or lenalidomide as a
part of first-line treatment increased from 29%-68% for
all patients in Sweden; this was even higher for the
patients under 65 years old in 2012 (87%).10 
The ten-year RSR did not improve significantly
between the first three calendar periods, but increased
significantly between the two last calendar periods, the
RSRs being 0.10 (95% CI: 0.09-0.12), 0.12 (95% CI: 0.11-
0.13), 0.14 (95% CI: 0.13-0.15) and 0.20 (95% CI: 0.18-
0.23), respectively, (Figure1). This is consistent with
results from clinical trials which have shown increasing
long-term survival, which has led authors to suggest that
MM could soon be classified as either a curable or chron-
ic disease.12
Three-month RSR increased in MM patients diagnosed
during the study period, although the improvement was
not significantly increased between the second and third
calendar periods, and in the four calendar periods result-
ed as 0.83 (95% CI: 0.82-0.84), 0.88 (95% CI: 0.87-0.89),
0.89 (95% CI: 0.88-0.90), and 0.93 (95% CI: 0.92-0.93),
respectively. The one-year RSR increased significantly
between all calendar periods, and was 0.69 (95% CI:
0.67-0.70), 0.74 (95% CI:  0.73-0.75), 0.77 (95% CI: 0.76-
0.78), and 0.82 (95% CI: 0.81-0.83) in the four calendar
periods, respectively. The three-month RSR increased in
all age groups from the first to the last calendar period,
although the increase was not significant in the two
youngest age groups (20-40 and 41-50 years at diagnosis;
Table 1). One-year RSR was significantly increased
between the first and last calendar periods for all age
groups, except that of  the youngest group where the RSR
did not change significantly. Similarly, in a recent study
from the USA, early mortality was higher between  2005
and 2010, compared to the rate between 2000 and 2005,
and early mortality was significantly lower in patients
receiving a novel agent as part of the initial treatment.13
Other possible contributing factors to improved short-
term survival include: early and aggressive treatment of
renal failure, hypercalcemia, infections, and venous
thromboembolism prophylaxis.14 Another consideration
is that patients may have been diagnosed at an earlier
stage of disease, although no data, to our knowledge, has
demonstrated this. 
The five-year and ten-year RSR increased significantly
between the first and last calendar periods for all age-
groups except for the youngest (20-40 years at diagnosis)
and the oldest group (>80 years old at diagnosis) where
the RSRs were similar (Table 1). In elderly patients, we
found that the five-year survival rate in the largest age
group, 71-80 years old at the time of diagnosis, increased
significantly between the last two calendar periods.
Furthermore, the ten-year relative survival for the same
age group was significantly increased in the last calendar
period, as compared to the first period. This is consistent
with a population-based study from the USA, where sur-
vival in MM patients diagnosed between 1973 and 2009
was found to be improved, over time, in all age groups up
to 80 years of age.3 It is, however, a point of concern that
there is no evidence of improvement in long-term relative
survival in patients over 80 years old at diagnosis during
the 40 years of the study. Although this age group repre-
sents 18% of all MM patients in our data, and is expected
to increase in number over time, limited data exist on
optimal treatment for these patients. Even in studies
focusing on “elderly” patients, those patients over 80
years old at the time of diagnosis are often not included.5
Therefore, in this group of patients, which are clearly not
benefitting from novel treatment options, more studies
are needed to detangle the underlying explanation, along
with clinical trials focusing on this large group of often
frail patients. 
Our study has several strengths, including the large
population-based design  with high-quality data, includ-
ing all MM patients reported to the Swedish Cancer
Register during a period of 40 years.15 Furthermore, the
collection of data was carried out prospectively,  inde-
pendent of our study. Limitations of the study herein
include lack of clinical data for individual patients, includ-
ing clinical stage of disease or the treatment each patient
received. This could improve to lead time bias if MM is
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Figure 2. Model-based estimates of five-
year relative survival ratios for four select-
ed values of age. RSR: relative survival
ratio.
detected at an earlier stage in the later calendar-periods. 
In conclusion, our large population-based study
showed that the survival of MM patients has been
improving dramatically, in particular during the last
decade. We believe this progress is due to the revolution-
ary changes in the therapeutic arsenal and supportive
care in MM. Further efforts are nevertheless needed for
the oldest patients, although the impact of newer treat-
ments is spreading to older age groups. Through ongoing
research and the introduction of agents with novel mech-
anisms of action, survival will hopefully continue to
improve in the coming years, as we make advances
towards changing MM to a chronic or a curable condi-
tion. 
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